Endothelial release of tissue-type plasminogen activator and ischemia- induced vasodilatation are linked in patients with coronary heart disease

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 4, 1999, Pages 181-187

  Sinisalo, Juha ^a   Syrjala M ^a   Mattila, K J ^a   Kerman, T ^a   Nieminen, M S ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Coronary heart disease; Endothelium; Fibrinolysis; Ischemia induced vasodilatation

Indexed keywords

ACETYLCHOLINE; NITROPRUSSIDE SODIUM; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; FOREARM BLOOD FLOW; HUMAN; ISCHEMIA; ISCHEMIC HEART DISEASE; MALE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROVOCATION TEST; STRAIN GAUGE TRANSDUCER; VASCULAR ENDOTHELIUM; VASODILATATION; VEIN OCCLUSION;

EID: 0032767342     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199906000-00004     Document Type: Article

References (44)

1. 1. Ross R. Mechanisms of disease: atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-121.
2. 2. Cines D, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al. Endothelial cells in physiology and in pathophysiology of vascular disorders. Blood 1998; 91: 3527-3561.
3. 3. Lüscher T. The endothelium and cardiovascular disease - a complex relation. N Engl J Med 1994; 330: 1081-1083.
4. 4. Sax F, Cannon RO, Hanson C, Epstein SE. Impaired forearm vasodilator reserve in patients with microvascular angina. Evidence of a generalized disorder of vascular function? N Engl J Med 1987; 317: 1366-1370.
5. 5. Ludmer P, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046-1051.
6. 6. Zeiher A, Drexler H, Wollschlänger H, Just H. Modulation of coronary vasomotor tone in human. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83: 391-401.
7. 7. Zeiher A, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow in humans: effect of age, atherosclerosis, hypercholesterolemia and hypertension. J Clin Invest 1993; 92: 652-662.
8. 8. Egashire K, Inou T, Hirooka Y, Yamada A, Ubare Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiogram. N Engl J Med 1993; 328: 1659-1664.
9. 9. Clarkson P, Celermajer DS, Powe AJ, Donald AE, Henry RMA, Deanfield JE. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation 1997; 96: 3378-3383.
10. 10. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 2057-2063.
11. 11. Thompson S, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 331: 417-424.
12. 12. Meade T, Mellows S, Brotzovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischaemic heart disease: principal results of Northwick Park Heart study. Lancet 1986; ii: 533-537.
13. 13. Anonymous. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8-17.
14. 14. Chowienczyk PJ, Cockcroft JR, Ritter JM. Differential inhibition by Ng-monomethyl-L-arginine of vasodilator effects of acetylcholine and methacholine in human forearm vasculature. Br J Pharmacol 1993; 110: 736-738.
15. 15. Hamsten A. The hemostatic system and coronary heart disease. Thromb Res 1993; 70: 1-38.
16. 16. Friedewald W, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
17. 17. Sinisalo J, Mattila K, Nieminen MS, Valtonen V, Syrjälä M, Sundberg S, et al. The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production. J Antimicrob Chemother 1998; 41: 85-92.
18. 18. Whitney R. The measurement of volume changes in human limbs. J Physiol (Lond) 1953; 121: 1-27.
19. 19. Kerslake D. The effect of application of an arterial occlusion cuff to wrist on the blood flow in the human forearm. J Physiol (Lond) 1949; 108: 451-457.
20. 20. Celermajer D, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
21. 21. Meredith I, Currie KE, Anderson TJ, Roddy M-A, Ganz P, Creager MA. Postischemic vasodilatation in human forearm is dependent on endothelium-derived nitric oxide. Am J Physiol 1996; 39: H1435-H1440.
22. 22. Patterson G, Whelan RF. Reactive hyperaemia in human forearm. Clin Sci 1955; 14: 197-211.
23. 23. Zeiher A. Endothelial vasodilator dysfunction: pathogenetic link to myocardial ischaemia or epiphenomenon? Lancet 1996; 348(suppl 1): S10-S12.
24. 24. Anderson T, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrande D, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1996; 26: 1235-1241.
25. 25. Stroes E, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication. Lancet 1995; 346: 467-471.
26. 26. Chowienczyk P, Watts GF, Cockcroft JR, Ritter JM. Impaired endothelium-dependent vasodilatation of forearm resistance vessels in hypercholesterolemia. Lancet 1992; 340: 1430-1432.
27. 27. Testa M, Biasucci LM, Cacciola M, Lombardo A, Pennestri F, Lejemtel TH, et al. Variable response of the peripheral circulation to acetylcholine in patients with coronary artery disease. J Am Cardiol 1996; 77: 149-153.
28. 28. Liao J, Bettmann MA, Sandor T, Tucer JI, Coleman SM, Creager MA. Differential impairment of vasodilatator responsiveness of peripheral resistance and conduit vessels in human atherosclerosis. Circ Res 1991; 68: 1027-1034.
29. 29. Francis R Jr, Kawanishi D, Baruch T, Mahrer P, Rahimtoola S, Feinstein DI. Impaired fibrinolysis in coronary artery disease. Am Heart J 1988; 115: 776-780.
30. 30. Syrjälä M, Kyusius T, Petäjä J, Vahtera E, Rasi V. Venous occlusion test: assessment of fibrinolytic capacity by D-dimer latex agglutination test. Fibrinolysis 1993; 7: 41-45.
31. 31. Keber D, Blinc A, Fettich J. Increase of tissue plasminogen activator in limbs during venous occlusion: a simple haemodynamic model. Thromb Haemost 1990; 64: 433-437.
32. 32. Booth N, Walker E, Meughan R, Bennett B. Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1. Blood 1987; 69: 1660-1604.
33. 33. Olofsson B, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10: 77-82.
34. 34. Zalewski A, Shi Y, Nardone D, Bravetti B, Weibstock P, Fisherman D, et al. Evidence for reduced fibrinolytic activity in unstable angina at rest. Clinical, biochemical and angiographic correlates. Circulation 1991; 83: 1685-1691.
35. 35. Vandekerckhove Y, Baele G, de Puydt H, Weyne A, Clement D. Plasma tissue plasminogen activator levels in patients with coronary heart disease. Thromb Res 1988; 50: 449-453.
36. 36. Oseroff A, Krishnamurti C, Hassett A, Tang D, Alving B. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary heart disease. J Lab Clin Med 1989; 113: 88-93.
37. 37. Hoffmeister H, Jur M, Ruf-Lehmann M, Helber U, Heller W, Seipel L. Endothelial tissue-type plasminogen activator release in coronary heart disease. Transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction. J Am Coll Cardiol 1998; 31: 547-551.
38. 38. Johnson O, Mellbring G, Nilsson T. Defective fibrinolysis in survivors of myocardial infarction. Int J Cardiol 1984; 6: 380-382.
39. 39. Chooi C, Gallus AS. Acute phase reaction, fibrinogen level and thrombus size. Thromb Res 1989; 53: 493-501.
40. 40. Naski M, Shafer JA. A kinetic model for the alpha-thrombin-catalyzed conversion of plasma levels of fibrinogen to fibrin in the presence of antithrombin III. J Biol Chem 1991; 26: 13003-13010.
41. 41. Meade T, Vickers MV, Thompson SG, Seghatchian MJ. The effect of physiological levels of fibrinogen on platelet aggregation. Thromb Res 1985; 38: 527-534.
42. 42. Meade T, Vickers MV, Thompson SG, Stirling Y, Haines AP. Epidemiological characteristics of platelet aggregability. BMJ 1985; 290: 428-432.
43. 43. Rubanyi G. The role of endothelium in cardiovascular homeostasis and disease. J Cardiovasc Pharmacol 1993; 22(suppl 4): S1-S14.
44. 44. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997; 96: 3042-3047.